Insilico expands Tenacia CNS pact in $94.75 million AI deal
CURRENT BRIEF VERSION: Insilico Medicine and Tenacia Biotechnology said on March 26, 2026, that they’re expanding their AI-driven central nervous system collaboration, adding a second program aimed at generating a new small-molecule candidate for difficult neurological diseases. The companies said the original collaboration, launched in March 2025, focused on small-molecule inhibitors designed for strong blood-brain barrier permeability, and that the expanded agreement could bring Insilico up to $94.75 million in near-term and milestone payments if development goals are met. Insilico, a clinical-stage AI drug discovery company listed in Hong Kong, said the new work will advance the added candidate to the preclinical candidate stage. The announcement also lands as Insilico broadens its larger partnering push: in a separate multi-program deal, Eli Lilly agreed to pay $115 million upfront for access to Insilico’s Pharma.AI platform and preclinical oral candidates in selected indications, with total potential value up to $2.75 billion plus tiered royalties. (prnewswire.com)
Why it matters: For veterinary professionals, this isn’t a companion animal deal, but it’s another marker that AI-enabled drug discovery is moving deeper into hard-to-treat neuroscience and into partnerships built around specific development milestones. That matters because Insilico says its Pharma.AI platform is also used across veterinary medicine, and broader validation of AI-led discovery in CNS drug design — along with a large multi-program Lilly alliance covering selected preclinical oral candidates and Lilly-chosen targets — could eventually influence how animal health companies approach neurologic, pain, and other brain-penetrant therapeutics. It also underscores the continued commercial appetite for platform companies that can shorten early discovery timelines and reduce the number of compounds that need to be synthesized and tested. (prnewswire.com)
What to watch: Watch for whether this Tenacia program reaches preclinical candidate nomination on the accelerated timelines Insilico has highlighted in other programs, and whether the company converts that momentum into more CNS or veterinary-facing partnerships. The scale and structure of the Lilly collaboration — upfront cash, multiple R&D programs, exclusive global rights, and downstream royalties — will also be worth watching as a benchmark for future AI-platform deals. (biospace.com)